Cencora | Pharma solutions in the news

Cencora assists health systems in enhancing pharmacy performance by managing operational complexities.

Cencora will release its Q4 financial results on November 4, with a webcast conference call featuring its CEO and CFO.

Cencora introduced a new Cell and Gene Therapy Enablement service to support health systems in managing complex treatments, positioning the company for growth in a rapidly expanding market.

Cencora shows strong growth in U.S. Healthcare Solutions and international operations, driven by specialty strength and acquisitions like OneOncology, despite challenges from drug-price reductions and regulatory uncertainty.

Cencora launched a Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems develop and expand CGT programs.

Cencora's Accelerate Pharmacy Solutions launched a new service to help health systems build and scale cell and gene therapy programs, focusing on financial confidence, operational readiness, and scalable growth.

Cencora executives Tim Weber and Kenzie Hohman explain how the company supports community pharmacies by identifying problems and providing solutions.

Cencora's Q3 revenue slightly surpassed expectations due to growth in Healthcare Solutions.

Distribution agreement with Kite to provide logistics and access for FDA-approved CAR T-cell therapies across U.S. healthcare providers.

ILC Dover has opened a new manufacturing facility in North Carolina to produce Water for Injection and custom chemicals for GLP-1 therapies and pharmaceutical production.

Analysis of the evolving pharmacy landscape, highlighting increased pharmacist autonomy and their critical role in mitigating the projected national physician shortage.

Piramal Pharma Solutions expanded its Michigan facility with a new payload-linker suite to accelerate Antibody-Drug Conjugate development as part of a $90 million US investment.

Piramal Pharma Solutions opened a new payload-linker suite in Michigan as part of a 90 million dollar US manufacturing expansion.

Pharma manufacturers are scaling cold chain infrastructure through AI integration and sustainable packaging to meet the surge in temperature-sensitive biologics and direct-to-patient therapies.

Piramal Pharma Solutions opened a specialized production suite in Michigan to expand its capacity for antibody drug conjugate manufacturing.

Cencora raised its annual profit forecast following solid Q2 results despite lowering revenue outlooks due to customer shifts and slower GLP-1 growth.

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have partnered to combine site-specific conjugation technology with global manufacturing for antibody-drug conjugate development.

Achieve Life Sciences moved cytisinicline manufacturing to Adare Pharma Solutions in the U.S., with a commercial launch expected in early 2027 despite previous FDA compliance observations at a third-party facility.

Sever Pharma Solutions appointed Niklas Lindgren as VP of Quality, bringing over 30 years of experience in quality management and regulatory compliance to the company.